Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T
Open Access
- 23 September 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (12) , 1496-1507
Abstract
Sipuleucel-T is an autologous cellular immunotherapy, administered as three infusions, for metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T induces T- and B-cell responses to prostatic acid phosphatase (PAP), correlating to improved survival. The long-term impact of sipuleucel-T on tumor antigen–specific immunologic memory remains unknown, in particular, B-cell responses, as measured by antigen-specific antibody responses and B-cell receptor (BCR) sequences. To evaluate whether sipuleucel-T could induce long-term immunologic memory, we examined circulating B-cell responses before and after sipuleucel-T treatment in two groups of patients with mCRPC: those who had previously received sipuleucel-T (treated; median, 8.9 years since the previous treatment) versus those who had not (naïve). Before re-treatment, previously treated patients exhibited persistent antibody responses as well as more focused and convergent BCR repertoires with distinct V(D)J gene usage compared with naïve patients. After re-treatment, previously treated patients maintained high-frequency clones and developed more convergent BCRs at earlier time points unlike naïve patients. With the first sipuleucel-T infusion specifically, previously treated patients had less shuffling within the 100 most abundant baseline clones. In contrast, naïve patients exhibited great BCR turnover with a continued influx of new B-cell clones. Social network analysis showed that previously treated patients had more highly organized B-cell repertoires, consistent with greater clonal maturation. Higher treatment-induced BCR clonality correlated with longer survival for naïve patients. These results demonstrated the capacity of sipuleucel-T to induce long-term immune memory and lasting changes to the B-cell repertoire.Keywords
All Related Versions
Funding Information
- NIH (4T32 CA177555, 1K08 AI139375)
- Conquer Cancer Foundation of the American Society of Clinical Oncology
- Prostate Cancer Foundation Young Investigator Award
- NIH (R01CA223484, U01CA233100)
- Prostate Cancer Foundation
This publication has 35 references indexed in Scilit:
- Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian CancerClinical Cancer Research, 2014
- Genetic measurement of memory B-cell recall using antibody repertoire sequencingProceedings of the National Academy of Sciences, 2013
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerCancer Immunology, Immunotherapy, 2012
- V(D)J Recombination: Mechanisms of InitiationAnnual Review of Genetics, 2011
- Understanding the Immunoglobulin Locus Specificity of Hypermutation2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Robust-Linear-Model Normalization To Reduce Technical Variability in Functional Protein MicroarraysJournal of Proteome Research, 2009
- MECHANISM AND CONTROL OF V(D)J RECOMBINATION AT THE IMMUNOGLOBULIN HEAVY CHAIN LOCUSAnnual Review of Immunology, 2006
- Human antibody–Fc receptor interactions illuminated by crystal structuresNature Reviews Immunology, 2004
- Somatic generation of antibody diversityNature, 1983